Abstract: OBJECTIVE To evaluate the efficacy and security of bevacizumab combined with platinum in the treatment of advanced non-small-cell lung cancer(NSCLC). METHODS Clinical literature of bevacizumab and platinum in treating NSCLC were collected from Pubmed, Elsevier sciencedirect, CENTRAL, CNKI, CBM, Wangfang and VIP etc. Review Manager 5.2 was used for Meta-analysis of overall remission, progression free survival, overall survival, adverse effects and death rate of advanced NSCLC treated with bevacizumab. RESULTS Seven papers were included. The Meta-anaylysis results suggested that ①high and low dose bevacizumab obviously improved overall remission rate and progression free survival of advanced NSCLC patients(P<0.000 01); ②high dose bevacizumab obviously prolonged overall survival of NSCLC patients(P<0.000 01), but low dose bevacizumab had no significant effect on ooverall survival; ③high and low dose bevacizumab could increase incidence of adverse effect without effect of motality. CONCLUSION Bevacizumab combined with platinum can obviously improve overall remission, progression free survival and overall survival of NSCLC patients, but it also increases incidence of adverse effects and can’t reduce motality.